title: Effects of perilipin 2 antisense oligonucleotide treatment on hepatic lipid metabolism and gene expression.
abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. We previously showed that Perilipin 2 (Plin2), a member of lipid droplet protein family, is markedly increased in fatty liver, and its reduction in the liver of diet-induced obese mice by antisense oligonucleotide (ASO) decreased steatosis and enhanced insulin sensitivity. Plin2-ASO treatment markedly suppressed lipogenic gene expression. To gain a better understanding of the biological role of Plin2 in liver, we performed microarray analysis to determine genes differentially regulated by Plin2-ASO compared with a control (scrambled) oligonucleotide (Cont). Male C57BL/6J mice on a high-fat diet were treated with Plin2- or Cont-ASO for 4 wk. Plin2-ASO decreased hepatic triglycerides, and this was associated with changes in expression of 1,363 genes. We analyzed the data for functional clustering and validated the expression of representative genes using real-time PCR. On the high-fat diet, Plin2-ASO decreased the expression of enzymes involved in fatty acid metabolism (acsl1, lipe) and steroid metabolism (hmgcr, hsd3b5, hsd17b2), suggesting that Plin2 affects hepatic lipid metabolism at the transcriptional level. Plin2-ASO also increased the expression of genes involved in regulation of hepatocyte proliferation (afp, H19), mitosis (ccna2, incenp, sgol1), and extracellular matrix (col1a1, col3a1, mmp8). Plin2-ASO had similar effects on gene expression in chow-fed mice. Together, these results indicate that Plin2 has diverse metabolic and structural roles in the liver, and its downregulation promotes hepatic fibrosis and proliferation.
authors.affiliation: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, and the Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104-5160, USA.
authors.forename: Yumi
authors.initials: Y
authors.lastname: Imai
authors.forename: Siobhan
authors.initials: S
authors.lastname: Boyle
authors.forename: Gladys M
authors.initials: GM
authors.lastname: Varela
authors.forename: Emilie
authors.initials: E
authors.lastname: Caron
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Yin
authors.forename: Raina
authors.initials: R
authors.lastname: Dhir
authors.forename: Ravindra
authors.initials: R
authors.lastname: Dhir
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Graham
authors.forename: Rexford S
authors.initials: RS
authors.lastname: Ahima
mesh_terms: D000818:Animals; D005234:Fatty Liver / Q000188:drug therapy; D015870:Gene Expression / Q000187:drug effects; D050356:Lipid Metabolism / Q000235:genetics / Q000502:physiology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D065626:Non-alcoholic Fatty Liver Disease; D016376:Oligonucleotides, Antisense / Q000235:genetics* / Q000627:therapeutic use*; D000070780:Perilipin-2
chemical_list: D008565:Membrane Proteins; D016376:Oligonucleotides, Antisense; D000070780:Perilipin-2; C000602983:Plin2 protein, mouse